OR2T33

Across TCGA pan-cancer cohorts, OR2T33 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated OR2T33 data layer compared with 6 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR2T33 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR2T33 expression acts as an unfavorable survival marker, although some lineages such as BRCA and SCLC show a favorable association.

LIHC, BLCA, and BRCA are the cancer types where OR2T33 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.178	0.723	<.001	90	view →
BLCA	OS	Tertile	All	0.063	0.688	<.001	84	view →
BRCA	OS	Quartile	III,IV	0.977	0.784	<.001	61	view →
COAD	OS	Tertile	III,IV	0.373	0.721	.003	60	view →
OV	OS	Tertile	IV	0.426	0.744	.001	50	view →
MESO	OS	Quartile	IV	0.208	0.649	.004	33	view →
READ	DFS	Tertile	IV	0.398	0.643	.004	18	view →
PRAD	OS	Quartile	All	0.771	0.969	.001	16	view →
LUSC	DFS	Tertile	III,IV	0.137	0.707	.020	15	view →
KIRP	OS	Tertile	All	0.748	0.911	.025	15	view →
PCPG	OS	Tertile	All	0.631	0.964	.034	9	view →
SCLC	DFS	Tertile	All	0.698	0.437	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

OR2T33–LIHC (OS)

Open the LIHC breakdown →